{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:21:53Z","timestamp":1788445313306,"version":"build-2803163510"},"reference-count":265,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,25]],"date-time":"2026-11-25T00:00:00Z","timestamp":1795564800000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01CA225753-05"],"award-info":[{"award-number":["1U01CA225753-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01GM130091-05"],"award-info":[{"award-number":["1R01GM130091-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001027","name":"CH Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["D-0005"],"award-info":[{"award-number":["D-0005"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030719","name":"National Institute of Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pharmr.2025.100101","type":"journal-article","created":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:42:21Z","timestamp":1761493341000},"page":"100101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Edaravone: Advances on cytoprotective effects, pharmacological properties, and mechanisms of action"],"prefix":"10.1016","volume":"78","author":[{"given":"Fatima","family":"Dakroub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4451-8533","authenticated-orcid":false,"given":"Bassel","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Abdelhady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7962","authenticated-orcid":false,"given":"Abdullah A.","family":"Shaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-5675","authenticated-orcid":false,"given":"Ali H.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8724-371X","authenticated-orcid":false,"given":"Joseph","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-3614","authenticated-orcid":false,"given":"Stefania","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina O.","family":"Bondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2682-5583","authenticated-orcid":false,"given":"Federico","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-7976","authenticated-orcid":false,"given":"Bahaa","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9343-6473","authenticated-orcid":false,"given":"Kevin K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3011-8718","authenticated-orcid":false,"given":"Elisa R.","family":"Zanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-6073","authenticated-orcid":false,"given":"Yehia","family":"Mechref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5008-6944","authenticated-orcid":false,"given":"Firas","family":"Kobeissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3164\/jcbn.17-62","article-title":"How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?","volume":"62","author":"Watanabe","year":"2018","journal-title":"J Clin Biochem Nutr"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/svn-2018-000221","article-title":"Safety and efficacy of edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc Neurol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/ph14080705","article-title":"Improved long-term survival with edaravone therapy in patients with amyotrophic lateral sclerosis: a retrospective single-center study in Japan","volume":"14","author":"Houzen","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal","year":"2019","journal-title":"Med Res Rev"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mus.27768","article-title":"Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment","volume":"67","author":"Genge","year":"2023","journal-title":"Muscle Nerve"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib7","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cpdd.925","article-title":"Evaluation of pharmacokinetics, safety, and drug-drug interactions of an oral suspension of edaravone in healthy adults","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib8","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1167\/iovs.10-6797","article-title":"Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment","volume":"52","author":"Roh","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/157489006775244191","article-title":"Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases","volume":"1","author":"Higashi","year":"2006","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neulet.2012.10.043","article-title":"Protective effect of edaravone against Alzheimer\u2019s disease-relevant insults in neuroblastoma N2a cells","volume":"531","author":"Yan","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmr.2025.100101_bib11","article-title":"Edaravone plays protective effects on LPS-induced microglia by switching M1\/M2 phenotypes and regulating NLRP3 inflammasome activation","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol, Internet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2004.10.037","article-title":"Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase","volume":"179","author":"Yoshida","year":"2005","journal-title":"Atherosclerosis"},{"issue":"48","key":"10.1016\/j.pharmr.2025.100101_bib13","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1038\/onc.2008.301","article-title":"JNK signaling in apoptosis","volume":"27","author":"Dhanasekaran","year":"2008","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-9255-5-7","article-title":"JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin","volume":"5","author":"Park","year":"2008","journal-title":"J Inflammm"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100101_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2017.1353101","article-title":"Edaravone and its clinical development for amyotrophic lateral sclerosis","volume":"18","author":"Takei","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13510002.1996.11747069","article-title":"Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one","volume":"2","author":"Yamamoto","year":"1996","journal-title":"Redox Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1527-3458.2006.00009.x","article-title":"Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury","volume":"12","author":"Yoshida","year":"2006","journal-title":"CNS Drug Rev"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0963689718755778","article-title":"Microenvironment imbalance of spinal cord injury","volume":"27","author":"Fan","year":"2018","journal-title":"Cell Transplant"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.111592","article-title":"Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro","volume":"384","author":"Homma","year":"2019","journal-title":"Exp Cell Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100101_bib20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.clinthera.2023.09.025","article-title":"Pharmacokinetics of edaravone oral suspension in patients with amyotrophic lateral sclerosis","volume":"45","author":"Shimizu","year":"2023","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.clinthera.2020.01.006","article-title":"Predicting the pharmacokinetic characteristics of edaravone intravenous injection and sublingual tablet through modeling and simulation","volume":"42","author":"Chen","year":"2020","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1124\/dmd.111.043356","article-title":"Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform","volume":"40","author":"Ma","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1177\/0018578717734877","article-title":"Formulary drug review: edaravone","volume":"52","author":"Ali","year":"2017","journal-title":"Hosp Pharm"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib24","first-page":"25","article-title":"Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis","volume":"43","author":"Cruz","year":"2018","journal-title":"P T"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1124\/dmd.106.013912","article-title":"Human organic anion transporters 1 (hOAT1\/SLC22A6) and 3 (hOAT3\/SLC22A8) transport edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and its sulfate conjugate","volume":"35","author":"Mizuno","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib26","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.107.016352","article-title":"Evaluation of the role of breast cancer resistance protein (BCRP\/ABCG2) and multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one)","volume":"35","author":"Mizuno","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmr.2025.100101_bib27","article-title":"The role of uptake and efflux transporters in the disposition of glucuronide and sulfate conjugates","volume":"12","author":"J\u00e4rvinen","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100101_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejps.2018.07.052","article-title":"Identification of the primary determining factor(s) governing the oral absorption of edaravone in rats","volume":"123","author":"Hyung","year":"2018","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cpdd.952","article-title":"Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib30","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s11033-020-05361-2","article-title":"Biological barriers, and the influence of protein binding on the passage of drugs across them","volume":"47","author":"Wanat","year":"2020","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.64719\/pb.4210","article-title":"Clinical significance of drug binding, protein binding, and binding displacement drug interactions","volume":"36","author":"DeVane","year":"2002","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12086","article-title":"Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT)","volume":"76","author":"Knights","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100101_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/21678421.2017.1353100","article-title":"Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations","volume":"18","author":"Nakamaru","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100101_bib34","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.clinthera.2022.10.001","article-title":"Food effect study to assess the impact on edaravone pharmacokinetic profiles in healthy participants","volume":"44","author":"Shimizu","year":"2022","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib35","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/IJN.S61288","article-title":"Current approaches to enhance CNS delivery of drugs across the brain barriers","volume":"9","author":"Lu","year":"2014","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10072-018-3653-2","article-title":"Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis","volume":"40","author":"Luo","year":"2019","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1254\/fpj.119.301","article-title":"Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent","volume":"119","author":"Tanaka","year":"2002","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.pharmr.2025.100101_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156521","article-title":"(+)-Borneol enhances the protective effect of edaravone against cerebral ischemia\/reperfusion injury by targeting OAT3\/P-gp transporters for drug delivery into the brain","volume":"139","author":"Wang","year":"2025","journal-title":"Phytomedicine"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cpt.1098","article-title":"Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium","volume":"104","author":"Yee","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2025.100101_bib40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejphar.2014.06.035","article-title":"The synergetic effect of edaravone and borneol in the rat model of ischemic stroke","volume":"740","author":"Wu","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib41","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jep.2013.10.028","article-title":"The mechanism of the opening of the blood-brain barrier by borneol: a pharmacodynamics and pharmacokinetics combination study","volume":"150","author":"Yu","year":"2013","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.pharmr.2025.100101_bib42","author":"Fong"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib43","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1039\/b925555a","article-title":"Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study","volume":"8","author":"Uzunova","year":"2010","journal-title":"Org Biomol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010514","article-title":"Toxicology and drug delivery by Cucurbit[n]uril type molecular containers","volume":"5","author":"Hettiarachchi","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib45","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.3390\/pharmaceutics14112281","article-title":"The improved brain-targeted drug delivery of edaravone temperature-sensitive gels by ultrasound for \u03b3-ray radiation-induced brain injury","volume":"14","author":"Li","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202101989","article-title":"Translating therapeutic microgels into clinical applications","volume":"11","author":"Kittel","year":"2022","journal-title":"Adv Healthc Mater"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib47","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1021\/acsabm.2c00325","article-title":"Targeted therapy of ischemic stroke via crossing the blood-brain barrier using edaravone-loaded multiresponsive microgels","volume":"5","author":"Lin","year":"2022","journal-title":"ACS Appl Bio Mater"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib48","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1038\/s41467-019-12426-9","article-title":"First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound","volume":"10","author":"Abrahao","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib49","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7150\/thno.18219","article-title":"Edaravone-encapsulated agonistic micelles rescue ischemic brain tissue by tuning blood-brain barrier permeability","volume":"7","author":"Jin","year":"2017","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib50","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1021\/nn5003375","article-title":"Overcoming the blood-brain barrier for delivering drugs into the brain by using adenosine receptor nanoagonist","volume":"8","author":"Gao","year":"2014","journal-title":"ACS Nano"},{"issue":"6415","key":"10.1016\/j.pharmr.2025.100101_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s10038-022-01055-8","article-title":"Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy","volume":"68","author":"Suzuki","year":"2023","journal-title":"J Hum Genet"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib53","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000669","article-title":"Progress in amyotrophic lateral sclerosis gene discovery: reflecting on classic approaches and leveraging emerging technologies","volume":"8","author":"Smukowski","year":"2022","journal-title":"Neurol Genet"},{"issue":"6438","key":"10.1016\/j.pharmr.2025.100101_bib54","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/364584a0","article-title":"ALS, SOD and peroxynitrite","volume":"364","author":"Beckman","year":"1993","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ana.410390210","article-title":"Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis","volume":"39","author":"Sikl\u00f3s","year":"1996","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib56","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn.2297","article-title":"A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice","volume":"12","author":"Saxena","year":"2009","journal-title":"Nat Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-510X(01)00661-X","article-title":"Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients","volume":"193","author":"Spreux-Varoquaux","year":"2002","journal-title":"J Neurol Sci"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100101_bib58","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.1073\/pnas.220417997","article-title":"Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis","volume":"97","author":"Johnston","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002849","article-title":"Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS","volume":"3","author":"Chang","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2025.100101_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.997661","article-title":"Misfolding at the synapse: a role in amyotrophic lateral sclerosis pathogenesis?","volume":"15","author":"Lum","year":"2022","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib61","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12883-022-02730-1","article-title":"Serum biomarkers of neuroinflammation and blood-brain barrier leakage in amyotrophic lateral sclerosis","volume":"22","author":"Cao","year":"2022","journal-title":"BMC Neurol"},{"key":"10.1016\/j.pharmr.2025.100101_bib62","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.brainres.2012.05.056","article-title":"Impaired blood-brain\/spinal cord barrier in ALS patients","volume":"1469","author":"Garbuzova-Davis","year":"2012","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib63","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nn2073","article-title":"ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration","volume":"11","author":"Zhong","year":"2008","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.pharmr.2025.100101_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114084","article-title":"Neurovascular unit pathology is observed very early in disease progression in the mutant SOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"353","author":"Yoshikawa","year":"2022","journal-title":"Exp Neurol"},{"issue":"B","key":"10.1016\/j.pharmr.2025.100101_bib65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.expneurol.2014.05.015","article-title":"Glial cells in amyotrophic lateral sclerosis","volume":"262","author":"Philips","year":"2014","journal-title":"Exp Neurol"},{"issue":"5778","key":"10.1016\/j.pharmr.2025.100101_bib66","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1126\/science.1123511","article-title":"Onset and progression in inherited ALS determined by motor neurons and microglia","volume":"312","author":"Boill\u00e9e","year":"2006","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036000","article-title":"Early functional deficit and microglial disturbances in a mouse model of amyotrophic lateral sclerosis","volume":"7","author":"Gerber","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib68","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000829","article-title":"Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis","volume":"7","author":"Dols-Icardo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.pharmr.2025.100101_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2009.10.026","article-title":"Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro","volume":"1307","author":"Lee","year":"2010","journal-title":"Brain Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100101_bib70","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1161\/STROKEAHA.113.002813","article-title":"Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice","volume":"44","author":"Miyamoto","year":"2013","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib71","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.expneurol.2008.07.017","article-title":"Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice","volume":"213","author":"Ito","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pharmr.2025.100101_bib72","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.brainres.2011.01.058","article-title":"Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger","volume":"1382","author":"Aoki","year":"2011","journal-title":"Brain Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140316","article-title":"Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse","volume":"10","author":"Ikeda","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13024-021-00510-y","article-title":"Edaravone activates the GDNF\/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells","volume":"17","author":"Li","year":"2022","journal-title":"Mol Neurodegener"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100101_bib75","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3390\/ph15070842","article-title":"The protective effect of edaravone on TDP-43 plus oxidative stress-induced neurotoxicity in neuronal cells: analysis of its neuroprotective mechanisms using RNA sequencing","volume":"15","author":"Soejima-Kusunoki","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib76","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jnr.24368","article-title":"Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis","volume":"97","author":"Ohta","year":"2019","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmr.2025.100101_bib77","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3389\/fneur.2018.00384","article-title":"A role for GDNF and soluble APP as biomarkers of amyotrophic lateral sclerosis pathophysiology","volume":"9","author":"Stanga","year":"2018","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib78","article-title":"Nrf2\/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS","volume":"2012","author":"Petri","year":"2012","journal-title":"Neurol Res Int"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib79","first-page":"e38","article-title":"Heart disease and stroke Statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Writing Group Members","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-022-01064-1","article-title":"Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.pharmr.2025.100101_bib81","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pneurobio.2017.10.001","article-title":"Blood-brain barrier dysfunction and recovery after ischemic stroke","volume":"163\u2013164","author":"Jiang","year":"2018","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmr.2025.100101_bib82","article-title":"Mechanisms of immune response and cell death in ischemic stroke and their regulation by natural compounds","volume":"14","author":"Gong","year":"2023","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2025.100101_bib83","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0006-8993(97)00490-3","article-title":"Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia","volume":"762","author":"Yamamoto","year":"1997","journal-title":"Brain Res"},{"issue":"2\u20133","key":"10.1016\/j.pharmr.2025.100101_bib84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2005.01.050","article-title":"Temporal effects of edaravone, a free radical scavenger, on transient ischemia-induced neuronal dysfunction in the rat hippocampus","volume":"512","author":"Otani","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100101_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.neuroscience.2011.01.017","article-title":"Edaravone alleviates delayed neuronal death and long-dated cognitive dysfunction of hippocampus after transient focal ischemia in Wistar rat brains","volume":"182","author":"Jiao","year":"2011","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib86","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.neures.2007.08.008","article-title":"Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia","volume":"59","author":"Ishikawa","year":"2007","journal-title":"Neurosci Res"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib87","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.bbrc.2009.09.015","article-title":"Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4","volume":"390","author":"Kikuchi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib88","first-page":"2437","article-title":"Protective effect of edaravone on blood-brain barrier by affecting NRF-2\/HO-1 signaling pathway","volume":"18","author":"Liu","year":"2019","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib89","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1248\/bpb.29.713","article-title":"Edaravone inhibits JNK-c-Jun pathway and restores anti-oxidative defense after ischemia-reperfusion injury in aged rats","volume":"29","author":"Wen","year":"2006","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/ph8020176","article-title":"Edaravone enhances brain-derived neurotrophic factor production in the ischemic mouse brain","volume":"8","author":"Okuyama","year":"2015","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib91","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/STROKEAHA.107.486654","article-title":"Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage","volume":"39","author":"Nakamura","year":"2008","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib92","article-title":"Exploring the mechanism of edaravone for oxidative stress in rats with cerebral infarction based on quantitative proteomics technology","volume":"2022","author":"Wang","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.pharmr.2025.100101_bib93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2016.08.048","article-title":"A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model","volume":"633","author":"Fujiwara","year":"2016","journal-title":"Neurosci Lett"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib94","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/01.STR.0000182241.07096.06","article-title":"Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain","volume":"36","author":"Zhang","year":"2005","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib95","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ams2.343","article-title":"Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke","volume":"5","author":"Matsumoto","year":"2018","journal-title":"Acute Med Surg"},{"issue":"B","key":"10.1016\/j.pharmr.2025.100101_bib96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuropharm.2018.06.005","article-title":"Secondary brain injury: predicting and preventing insults","volume":"145","author":"Lazaridis","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmr.2025.100101_bib97","article-title":"Neuroinflammation following traumatic brain injury: take it seriously or not","volume":"13","author":"Zheng","year":"2022","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100101_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113000","article-title":"Oxidative stress in traumatic brain injury","volume":"23","author":"Fesharaki-Zadeh","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib99","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1038\/s41598-022-10419-1","article-title":"Time dependent analysis of rat microglial surface markers in traumatic brain injury reveals dynamics of distinct cell subpopulations","volume":"12","author":"Gottlieb","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib100","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1007\/s12640-022-00566-8","article-title":"Extracellular mitochondria activate microglia and contribute to neuroinflammation in traumatic brain injury","volume":"40","author":"Zhang","year":"2022","journal-title":"Neurotox Res"},{"key":"10.1016\/j.pharmr.2025.100101_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105080","article-title":"Long-lasting blood-brain barrier dysfunction and neuroinflammation after traumatic brain injury","volume":"145","author":"van Vliet","year":"2020","journal-title":"Neurobiol Dis"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib102","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1474-4422(17)30279-X","article-title":"The chronic and evolving neurological consequences of traumatic brain injury","volume":"16","author":"Wilson","year":"2017","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrneurol.2017.13","article-title":"The far-reaching scope of neuroinflammation after traumatic brain injury","volume":"13","author":"Simon","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100101_bib104","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1089\/neu.2014.3331","article-title":"Suppression of oxidative stress and 5-lipoxygenase activation by edaravone improves depressive-like behavior after concussion","volume":"31","author":"Higashi","year":"2014","journal-title":"J Neurotrauma"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12640-009-9081-6","article-title":"The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury","volume":"16","author":"Itoh","year":"2009","journal-title":"Neurotox Res"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib106","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1089\/neu.2011.1939","article-title":"Free-radical scavenger edaravone treatment confers neuroprotection against traumatic brain injury in rats","volume":"28","author":"Wang","year":"2011","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharmr.2025.100101_bib107","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.brainres.2012.09.011","article-title":"Attenuation of axonal injury and oxidative stress by edaravone protects against cognitive impairments after traumatic brain injury","volume":"1490","author":"Ohta","year":"2013","journal-title":"Brain Res"},{"key":"10.1016\/j.pharmr.2025.100101_bib108","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/379206","article-title":"Therapeutic time window for edaravone treatment of traumatic brain injury in mice","volume":"2013","author":"Miyamoto","year":"2013","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib109","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3892\/etm.2022.11394","article-title":"Edaravone attenuates traumatic brain injury through anti-inflammatory and anti-oxidative modulation","volume":"18","author":"Zhang","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.pharmr.2025.100101_bib110","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e3131","article-title":"Edaravone improves the post-traumatic brain injury dysfunction in learning and memory by modulating Nrf2\/ARE signal pathway","volume":"76","author":"Li","year":"2021","journal-title":"Clinics"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib111","doi-asserted-by":"crossref","first-page":"514","DOI":"10.5114\/aoms.2019.89849","article-title":"Edaravone attenuates neuronal apoptosis in hippocampus of rat traumatic brain injury model via activation of BDNF\/TrkB signaling pathway","volume":"17","author":"Ding","year":"2021","journal-title":"Arch Med Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib112","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11064-009-0061-2","article-title":"Edaravone protects against apoptotic neuronal cell death and improves cerebral function after traumatic brain injury in rats","volume":"35","author":"Itoh","year":"2010","journal-title":"Neurochem Res"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100101_bib113","doi-asserted-by":"crossref","first-page":"10448","DOI":"10.1007\/s12035-024-04216-2","article-title":"Edaravone alleviates traumatic brain injury by inhibition of ferroptosis via FSP1 pathway","volume":"61","author":"Shi","year":"2024","journal-title":"Mol Neurobiol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100101_bib114","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Abe","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharmr.2025.100101_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101590","article-title":"Intravenous edaravone treatment in ALS and survival: an exploratory, retrospective, administrative claims analysis","volume":"52","author":"Brooks","year":"2022","journal-title":"EClinicalmedicine"},{"issue":"7\u20138","key":"10.1016\/j.pharmr.2025.100101_bib116","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100101_bib117","first-page":"11","article-title":"A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258614","article-title":"Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: post-hoc analysis of study 19 (MCI186-19) [clinical trial NCT01492686]","volume":"17","author":"Brooks","year":"2022","journal-title":"PLoS One"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2025.100101_bib119","first-page":"40","article-title":"Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation)","volume":"18","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1159\/000210190","article-title":"Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial)","volume":"27","author":"Shinohara","year":"2009","journal-title":"Cerebrovasc Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib121","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11586550-000000000-00000","article-title":"Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study","volume":"10","author":"Naritomi","year":"2010","journal-title":"Drugs R D"},{"key":"10.1016\/j.pharmr.2025.100101_bib122","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2377-11-39","article-title":"Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke","volume":"11","author":"Nakase","year":"2011","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib123","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaneurol.2023.5716","article-title":"Sublingual edaravone dexborneol for the treatment of acute ischemic stroke: the TASTE-SL randomized clinical trial","volume":"81","author":"Fu","year":"2024","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib124","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/STROKEAHA.120.031197","article-title":"Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"issue":"1\u20132","key":"10.1016\/j.pharmr.2025.100101_bib125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jns.2011.09.006","article-title":"Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients \u2014 A preliminary study","volume":"313","author":"Kimura","year":"2012","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib126","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/STROKEAHA.118.023815","article-title":"Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy","volume":"50","author":"Enomoto","year":"2019","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib127","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1089\/neu.2006.23.1591","article-title":"Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury","volume":"23","author":"Dohi","year":"2006","journal-title":"J Neurotrauma"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib128","first-page":"25","article-title":"Effects of decompressive craniectomy combined with edaravone on postoperative neurological functions and hemodynamics of patients with severe traumatic brain injury","volume":"29","author":"Yang","year":"2024","journal-title":"Neurosciences"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11634290-000000000-00000","article-title":"Phase I clinical study of edaravone in healthy Chinese volunteers: safety and pharmacokinetics of single or multiple intravenous infusions","volume":"12","author":"Li","year":"2012","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/cpdd.814","article-title":"A randomized, single-blind, placebo-controlled, 3-way crossover study to evaluate the effect of therapeutic and supratherapeutic doses of edaravone on QT\/QTc interval in healthy subjects","volume":"10","author":"Shimizu","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib131","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.clinthera.2020.06.020","article-title":"An open-label, single-dose study to evaluate the pharmacokinetic variables of edaravone in subjects with mild, moderate, or no renal impairment","volume":"42","author":"Nakamaru","year":"2020","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib132","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.clinthera.2020.06.016","article-title":"Open-label, single-dose studies of the pharmacokinetics of edaravone in subjects with mild, moderate, or severe hepatic impairment compared to subjects with normal hepatic functioning","volume":"42","author":"Nakamaru","year":"2020","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib133","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10072-019-04055-3","article-title":"Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients","volume":"41","author":"Park","year":"2020","journal-title":"Neurol Sci"},{"issue":"suppl1","key":"10.1016\/j.pharmr.2025.100101_bib134","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/21678421.2017.1362440","article-title":"A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies","volume":"18","author":"Kalin","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1016\/j.pharmr.2025.100101_bib135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jns.2019.06.006","article-title":"Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy","volume":"404","author":"Fortuna","year":"2019","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib136","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s13760-020-01382-7","article-title":"Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina","volume":"121","author":"Quarracino","year":"2021","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib137","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jcpt.13392","article-title":"Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: a meta-analysis of randomized controlled trials","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib138","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4103\/njcp.njcp_367_18","article-title":"Clinical observation in edaravone treatment for acute cerebral infarction","volume":"22","author":"Sun","year":"2019","journal-title":"Niger J Clin Pract"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib139","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s10157-007-0495-2","article-title":"Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance","volume":"11","author":"Hishida","year":"2007","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/17482960600881870","article-title":"Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)","volume":"7","author":"Yoshino","year":"2006","journal-title":"Amyotroph Lateral Scler"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib143","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s10072-023-06869-8","article-title":"Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"44","author":"Nourelden","year":"2023","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-022-01229-4","article-title":"Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"43","author":"Gao","year":"2023","journal-title":"Clin Drug Investig"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100101_bib145","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026127","article-title":"Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone","volume":"100","author":"Kakimoto","year":"2021","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib146","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpdd.1175","article-title":"Edaravone administered orally and via nasogastric tube in healthy adults: a comparative bioavailability Phase 1 study","volume":"12","author":"Shimizu","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib147","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12883-022-02788-x","article-title":"Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study","volume":"22","author":"Park","year":"2022","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib148","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel","year":"2022","journal-title":"JAMA Neurol"},{"issue":"7\u20138","key":"10.1016\/j.pharmr.2025.100101_bib149","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/21678421.2019.1645858","article-title":"Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch","volume":"20","author":"Jackson","year":"2019","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib150","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40268-022-00391-6","article-title":"Analysis of the US safety data for edaravone (Radicava\u00ae) from the third year after launch","volume":"22","author":"Genge","year":"2022","journal-title":"Drugs R D"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib151","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.05.018","article-title":"Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka stroke registry","volume":"22","author":"Kamouchi","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib152","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1744-9987.2007.00480.x","article-title":"A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient","volume":"11","author":"Abe","year":"2007","journal-title":"Ther Apher Dial"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib153","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/jcpt.12748","article-title":"Surveillance of drugs that most frequently induce acute kidney injury: a pharmacovigilance approach","volume":"44","author":"Hosohata","year":"2019","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib154","doi-asserted-by":"crossref","first-page":"293","DOI":"10.26599\/1671-5411.2023.04.002","article-title":"Safety of butylphthalide and edaravone in patients with ischemic stroke: a multicenter real-world study","volume":"20","author":"Lyu","year":"2023","journal-title":"J Geriatr Cardiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib155","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/pharmaceutics16080993","article-title":"Edaravone for the treatment of motor neurone disease: a critical review of approved and alternative formulations against a proposed quality target product profile","volume":"16","author":"O\u2019Neill","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharmr.2025.100101_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2019.10.003","article-title":"Neurological disorders and mitochondria","volume":"71","author":"Cabral-Costa","year":"2020","journal-title":"Mol Aspects Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib157","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-020-00107-x","article-title":"Mitochondrial dysfunction in neurological disorders: exploring mitochondrial transplantation","volume":"5","author":"Norat","year":"2020","journal-title":"npj Regen Med"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100101_bib158","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00018-013-1550-7","article-title":"Neuronal calcium signaling: function and dysfunction","volume":"71","author":"Brini","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pharmr.2025.100101_bib159","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mito.2019.07.003","article-title":"Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling","volume":"49","author":"Wu","year":"2019","journal-title":"Mitochondrion"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib160","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/STROKEAHA.117.019687","article-title":"Critical role of flavin and glutathione in complex I\u2013mediated bioenergetic failure in brain ischemia\/reperfusion injury","volume":"49","author":"Kahl","year":"2018","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib161","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.freeradbiomed.2009.02.008","article-title":"Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation","volume":"46","author":"Tahara","year":"2009","journal-title":"Free Radic Biol Med"},{"issue":"7527","key":"10.1016\/j.pharmr.2025.100101_bib162","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature13909","article-title":"Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS","volume":"515","author":"Chouchani","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib163","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40659-020-00297-0","article-title":"Edaravone alleviates cell apoptosis and mitochondrial injury in ischemia-reperfusion-induced kidney injury via the JAK\/STAT pathway","volume":"53","author":"Zhao","year":"2020","journal-title":"Biol Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib164","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1248\/bpb.b20-00085","article-title":"Edaravone improves intermittent hypoxia-induced cognitive impairment and hippocampal damage in rats","volume":"43","author":"Ling","year":"2020","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MAJ.0000000000000506","article-title":"Traumatic brain injury and mitochondrial dysfunction","volume":"350","author":"Hiebert","year":"2015","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.pharmr.2025.100101_bib166","first-page":"97","article-title":"Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities","volume":"11","author":"Lozano","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100101_bib167","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/neu.2008.0586","article-title":"Classification of traumatic brain injury for targeted therapies","volume":"25","author":"Saatman","year":"2008","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.pharmr.2025.100101_bib168","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3389\/fncel.2015.00434","article-title":"Compartment-dependent mitochondrial alterations in experimental ALS, the effects of mitophagy and mitochondriogenesis","volume":"9","author":"Natale","year":"2015","journal-title":"Front Cell Neurosci"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100101_bib169","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1096\/fj.02-1182fje","article-title":"Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis","volume":"17","author":"Dupuis","year":"2003","journal-title":"FASEB J"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib170","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.neuron.2010.07.019","article-title":"Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS","volume":"67","author":"Israelson","year":"2010","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib171","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/nen.0b013e31802c396b","article-title":"Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis","volume":"66","author":"Sasaki","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib172","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/j.1471-4159.2006.03619.x","article-title":"Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu\/Zn-superoxide dismutase mutant mice","volume":"96","author":"Damiano","year":"2006","journal-title":"J Neurochem"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100101_bib173","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/jnr.24249","article-title":"Discrete mitochondrial aberrations in the spinal cord of sporadic ALS patients","volume":"96","author":"Delic","year":"2018","journal-title":"J Neurosci Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib174","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1096\/fj.201801843R","article-title":"Distinction of sporadic and familial forms of ALS based on mitochondrial characteristics","volume":"33","author":"Walczak","year":"2019","journal-title":"FASEB J"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0006-8993(01)02012-1","article-title":"Intrathecal cyclosporin prolongs survival of late-stage ALS mice","volume":"894","author":"Keep","year":"2001","journal-title":"Brain Res"},{"issue":"33","key":"10.1016\/j.pharmr.2025.100101_bib176","doi-asserted-by":"crossref","first-page":"29626","DOI":"10.1074\/jbc.M203065200","article-title":"Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice","volume":"277","author":"Mattiazzi","year":"2002","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib177","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1254\/jphs.SC0070014","article-title":"Edaravone, a radical scavenger, inhibits mitochondrial permeability transition pore in rat brain","volume":"103","author":"Takayasu","year":"2007","journal-title":"J Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib178","article-title":"Protective effect of edaravone against carbon monoxide induced apoptosis in rat primary cultured astrocytes","volume":"2017","author":"Xu","year":"2017","journal-title":"Biochem Res Int"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib179","article-title":"Oxidative stress in neurodegeneration","volume":"2011","author":"Shukla","year":"2011","journal-title":"Adv Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib180","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6635460","article-title":"The Keap1-Nrf2 system: a mediator between oxidative stress and aging","volume":"2021","author":"Yu","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100101_bib181","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.3390\/ijms21134777","article-title":"NRF2, a transcription factor for stress response and beyond","volume":"21","author":"He","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01616412.2017.1376457","article-title":"Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK\/Nrf2\/HO-1 signaling pathway","volume":"40","author":"Zhang","year":"2018","journal-title":"Neurol Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib183","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3892\/ijo.2020.5077","article-title":"Protective effects of combined treatment with mild hypothermia and edaravone against cerebral ischemia\/reperfusion injury via oxidative stress and Nrf2 pathway regulation","volume":"57","author":"Yu","year":"2020","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib184","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/fcp.12782","article-title":"Edaravone dexborneol protects cerebral ischemia reperfusion injury through activating Nrf2\/HO-1 signaling pathway in mice","volume":"36","author":"Xu","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib185","article-title":"Edaravone dexborneol alleviates cerebral ischemic injury via MKP-1-mediated inhibition of MAPKs and activation of Nrf2","volume":"2022","author":"Zhang","year":"2022","journal-title":"Biomed Res Int Salto R, ed"},{"key":"10.1016\/j.pharmr.2025.100101_bib186","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.freeradbiomed.2018.07.002","article-title":"Mkp-1 cross-talks with Nrf2\/Ho-1 pathway protecting against intestinal inflammation","volume":"124","author":"Li","year":"2018","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib187","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.4103\/1673-5374.169606","article-title":"A role for mitogen-activated protein kinase phosphatase 1 (MKP1) in neural cell development and survival","volume":"10","author":"Toulouse","year":"2015","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib188","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12974-022-02400-6","article-title":"Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1\/Nrf2\/HO-1\/Gpx4 pathway","volume":"19","author":"Dang","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.pharmr.2025.100101_bib189","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.taap.2015.12.024","article-title":"Dioscin alleviates BDL- and DMN-induced hepatic fibrosis via Sirt1\/Nrf2-mediated inhibition of p38 MAPK pathway","volume":"292","author":"Gu","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100101_bib190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fnins.2020.00267","article-title":"Nrf2 and ferroptosis: a new research direction for neurodegenerative diseases","volume":"14","author":"Song","year":"2020","journal-title":"Front Neurosci"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib191","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011254","article-title":"MAP kinase pathways","volume":"4","author":"Morrison","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.pharmr.2025.100101_bib192","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2013.02.067","article-title":"Edaravone alleviates hypoxia-acidosis\/reoxygenation-induced neuronal injury by activating ERK1\/2","volume":"543","author":"Wang","year":"2013","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pharmr.2025.100101_bib193","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuro.2018.06.008","article-title":"Methylmercury induces oxidative stress and subsequent neural hyperactivity leading to cell death through the p38 MAPK-CREB pathway in differentiated SH-SY5Y cells","volume":"67","author":"Fujimura","year":"2018","journal-title":"NeuroToxicology"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib194","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cns.12044","article-title":"Edaravone protects HT22 neurons from H2O2-induced apoptosis by inhibiting the MAPK signaling pathway","volume":"19","author":"Zhao","year":"2013","journal-title":"CNS Neurosci Ther"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100101_bib195","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/glia.20541","article-title":"Nitric oxide-induced apoptosis in cultured rat astrocytes: protection by edaravone, a radical scavenger","volume":"55","author":"Kawasaki","year":"2007","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib196","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1124\/jpet.108.148676","article-title":"Edaravone, a free radical scavenger, protects against retinal damage in vitro and in vivo","volume":"329","author":"Inokuchi","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"10.1016\/j.pharmr.2025.100101_bib197","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2010.05.057","article-title":"Systemic administration of a free radical scavenger, edaravone, protects against light-induced photoreceptor degeneration in the mouse retina","volume":"642","author":"Imai","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib198","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.3390\/ijms21113858","article-title":"Relevance of SIRT1-NF-\u03baB axis as therapeutic target to ameliorate inflammation in liver disease","volume":"21","author":"de Gregorio","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib199","first-page":"218","article-title":"Effects of edaravone combined with oxiracetam on neuronal apoptosis in rats with cerebral infarction through targeting SIRT1\/NF-\u03baB inflammatory pathway","volume":"26","author":"Cui","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib200","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.cellsig.2013.06.007","article-title":"Antagonistic crosstalk between NF-\u03baB and SIRT1 in the regulation of inflammation and metabolic disorders","volume":"25","author":"Kauppinen","year":"2013","journal-title":"Cell Signal"},{"issue":"3 suppl","key":"10.1016\/j.pharmr.2025.100101_bib201","first-page":"17","article-title":"Edaravone protects from retinal injury through NF-\u03baB in diabetic rats","volume":"23","author":"Wan","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2025.100101_bib202","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/JIR.S252659","article-title":"Pristimerin inhibits MMP-9 expression and cell migration through attenuating NOX\/ROS-dependent NF-\u03baB activation in rat brain astrocytes challenged with LPS","volume":"13","author":"Yang","year":"2020","journal-title":"J Inflamm Res"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib203","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.bbrc.2015.02.029","article-title":"NLRP3 inflammasome expression is driven by NF-\u03baB in cultured hepatocytes","volume":"458","author":"Boaru","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104468","article-title":"Edaravone administration confers neuroprotection after experimental intracerebral hemorrhage in rats via NLRP3 suppression","volume":"29","author":"Miao","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"A","key":"10.1016\/j.pharmr.2025.100101_bib205","article-title":"Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke","volume":"113","author":"Hu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"5879","key":"10.1016\/j.pharmr.2025.100101_bib206","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1126\/science.1158265","article-title":"Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins","volume":"320","author":"Benhar","year":"2008","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib207","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/fcp.12556","article-title":"Edaravone inhibits procaspase-3 denitrosylation and activation through FASL-Trx2 pathway in KA-induced seizure","volume":"34","author":"Hao","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF03033912","article-title":"Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats","volume":"12","author":"Xiao","year":"2007","journal-title":"Neurotox Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib209","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/13880209.2021.1972123","article-title":"Edaravone prevents high glucose-induced injury in retinal M\u00fcller cells through thioredoxin1 and the PGC-1\u03b1\/NRF1\/TFAM pathway","volume":"59","author":"Yin","year":"2021","journal-title":"Pharm Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib210","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/bab.1821","article-title":"Lutein upregulates the PGC-1\u03b1, NRF1, and TFAM expression by AMPK activation and downregulates ROS to maintain mtDNA integrity and mitochondrial biogenesis in hyperglycemic ARPE-19 cells and rat retina","volume":"66","author":"Nanjaiah","year":"2019","journal-title":"Biotechnol Appl Biochem"},{"issue":"9\u201310","key":"10.1016\/j.pharmr.2025.100101_bib211","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1089\/ars.2006.8.1635","article-title":"Thioredoxin1 upregulates mitochondrial proteins related to oxidative phosphorylation and TCA cycle in the heart","volume":"8","author":"Ago","year":"2006","journal-title":"Antioxid Redox Signal"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib212","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/sj.embor.7400779","article-title":"Mediators of endoplasmic reticulum stress-induced apoptosis","volume":"7","author":"Szegezdi","year":"2006","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharmr.2025.100101_bib213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2013.04.037","article-title":"Edaravone protects against glutamate-induced PERK\/EIF2\u03b1\/ATF4 integrated stress response and activation of caspase-12","volume":"1519","author":"Fan","year":"2013","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib214","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1124\/jpet.104.069088","article-title":"Edaravone protects against hypoxia\/ischemia-induced endoplasmic reticulum dysfunction","volume":"311","author":"Qi","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib215","first-page":"2319","article-title":"The Akt pathway in oncology therapy and beyond (Review)","volume":"53","author":"Nitulescu","year":"2018","journal-title":"Int J Oncol"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100101_bib216","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1074\/jbc.275.15.10761","article-title":"Akt\/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein","volume":"275","author":"Pugazhenthi","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2025.100101_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2019.103399","article-title":"Edaravone protects primary-cultured rat cortical neurons from ketamine-induced apoptosis via reducing oxidative stress and activating PI3K\/Akt signal pathway","volume":"100","author":"Li","year":"2019","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.pharmr.2025.100101_bib218","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ibror.2020.04.003","article-title":"Edaravone protects rat astrocytes from oxidative or neurotoxic inflammatory insults by restoring Akt\/Bcl-2\/caspase-3 signaling axis","volume":"8","author":"Guo","year":"2020","journal-title":"IBRO Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib219","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153708","article-title":"Protective effects of edaravone in adult rats with surgery and lipopolysaccharide administration-induced cognitive function impairment","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib220","first-page":"237","article-title":"BDNF function and intracellular signaling in neurons","volume":"25","author":"Numakawa","year":"2010","journal-title":"Histol Histopathol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib221","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0896-6273(00)81010-7","article-title":"Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism","volume":"20","author":"Tao","year":"1998","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100101_bib222","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1111\/jcmm.16422","article-title":"Edaravone alleviated propofol-induced neural injury in developing rats by BDNF\/TrkB pathway","volume":"25","author":"Yang","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.pharmr.2025.100101_bib223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuro.2021.06.003","article-title":"Edaravone attenuates cadmium-induced toxicity by inhibiting oxidative stress and inflammation in ICR mice","volume":"86","author":"Fan","year":"2021","journal-title":"NeuroToxicology"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib224","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI126655","article-title":"Roles of HIFs and VEGF in angiogenesis in the retina and brain","volume":"129","author":"Rattner","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100101_bib225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuroscience.2011.11.005","article-title":"Treatment with edaravone attenuates ischemic brain injury and inhibits neurogenesis in the subventricular zone of adult rats after focal cerebral ischemia and reperfusion injury","volume":"201","author":"Zhang","year":"2012","journal-title":"Neuroscience"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100101_bib226","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.3390\/ijms21134609","article-title":"HMGB1-mediated neuroinflammatory responses in brain injuries: potential mechanisms and therapeutic opportunities","volume":"21","author":"Paudel","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib227","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.108.149484","article-title":"The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells","volume":"329","author":"Kikuchi","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmr.2025.100101_bib228","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuint.2017.07.001","article-title":"Neuroprotection of edaravone on the hippocampus of kainate-induced epilepsy rats through Nrf2\/HO-1 pathway","volume":"112","author":"Liu","year":"2018","journal-title":"Neurochem Int"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib229","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/aps.2016.71","article-title":"Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2\/HO-1 pathway","volume":"37","author":"Li","year":"2016","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib230","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s12035-017-0513-7","article-title":"Roles of nitric oxide synthase isoforms in neurogenesis","volume":"55","author":"Chong","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib231","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib232","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/1673-5374.175046","article-title":"Lipid mediators of inflammation in neurological injury: shifting the balance toward resolution","volume":"11","author":"Harrison","year":"2016","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.pharmr.2025.100101_bib233","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.expneurol.2014.03.008","article-title":"Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits","volume":"256","author":"Corser-Jensen","year":"2014","journal-title":"Exp Neurol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib234","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1631\/jzus.2006.B0749","article-title":"Edaravone protects PC12 cells from ischemic-like injury via attenuating the damage to mitochondria","volume":"7","author":"Song","year":"2006","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.pharmr.2025.100101_bib235","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.brainres.2018.03.006","article-title":"Edaravone, a free radical scavenger, protects neuronal cells\u2019 mitochondria from ischemia by inactivating another new critical factor of the 5-lipoxygenase pathway affecting the arachidonic acid metabolism","volume":"1690","author":"Song","year":"2018","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib236","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2045-9912-1-12","article-title":"Improved brain MRI indices in the acute brain stem infarct sites treated with hydroxyl radical scavengers, edaravone and hydrogen, as compared to edaravone alone. A non-controlled study","volume":"1","author":"Ono","year":"2011","journal-title":"Med Gas Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib237","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098807","article-title":"Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib238","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/STROKEAHA.116.015042","article-title":"Yamato study (tissue-type plasminogen activator and edaravone combination therapy)","volume":"48","author":"Aoki","year":"2017","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib239","first-page":"109","article-title":"Safety and efficacy of edaravone combined with alteplase for patients with acute ischemic stroke: a systematic review and meta-analysis","volume":"76","author":"Hu","year":"2021","journal-title":"Pharmazie"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib240","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.10.011","article-title":"Edaravone with and without 0.6 Mg\/Kg alteplase within 4.5 hours after ischemic stroke: a prospective cohort study (PROTECT4.5)","volume":"26","author":"Yamaguchi","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib241","article-title":"Effect of edaravone combined with anticoagulant therapy on the serum hs-CRP, IL-6, and TNF-\u03b1 levels and activity of daily living in patients with acute cerebral infarction","volume":"2022","author":"Sun","year":"2022","journal-title":"J Healthc Eng"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib242","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.expneurol.2008.09.004","article-title":"The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator","volume":"215","author":"Lapchak","year":"2009","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib243","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0168-0102(02)00019-6","article-title":"Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils","volume":"43","author":"Jin","year":"2002","journal-title":"Neurosci Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib244","first-page":"646","article-title":"Edaravone combined with cinepazide maleate on neurocyte autophagy and neurological function in rats with subarachnoid hemorrhage","volume":"19","author":"Cai","year":"2020","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100101_bib245","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4314\/tjpr.v20i4.29","article-title":"Changes in nerve function and endothelin level in patients with cerebral infarction after treatment with a combination of urinary kallidinogenase and edaravone","volume":"20","author":"Yan","year":"2022","journal-title":"Trop J Pharm Res"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib246","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3892\/br.2016.692","article-title":"Analysis of treatment effect of urinary kallidinogenase combined with edaravone on massive cerebral infarction","volume":"5","author":"Ke","year":"2016","journal-title":"Biomed Rep"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100101_bib247","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2431","article-title":"Human urinary kallidinogenase combined with edaravone in treating acute ischemic stroke patients: a meta-analysis","volume":"11","author":"Yang","year":"2021","journal-title":"Brain Behav"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib248","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neulet.2008.06.033","article-title":"Combination effects of normobaric hyperoxia and edaravone on focal cerebral ischemia-induced neuronal damage in mice","volume":"441","author":"Nonaka","year":"2008","journal-title":"Neurosci Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib249","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s12013-015-0584-x","article-title":"Early combined therapy with pharmacologically induced hypothermia and edaravone exerts neuroprotective effects in a rat model of intracerebral hemorrhage","volume":"73","author":"Zhu","year":"2015","journal-title":"Cell Biochem Biophys"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib250","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4103\/1673-5374.152376","article-title":"Edaravone combined with Schwann cell transplantation may repair spinal cord injury in rats","volume":"10","author":"Zhang","year":"2015","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib251","first-page":"223","article-title":"Curative efficacy of penehyclidine combined with edaravone on acute cerebral infarction and their effects on serum TNF-\u03b1 and NDS score in rats","volume":"22","author":"Chen","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2025.100101_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134438","article-title":"Edaravone-caffeine combination for the effective management of rotenone induced Parkinson\u2019s disease in rats: an evidence based affirmative from a comparative analysis of behavior and biomarker expression","volume":"711","author":"Bandookwala","year":"2019","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100101_bib253","first-page":"371","article-title":"The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction","volume":"73","author":"Shen","year":"2022","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.pharmr.2025.100101_bib254","doi-asserted-by":"crossref","DOI":"10.3389\/fnbot.2021.719145","article-title":"Magnetic resonance imaging image segmentation under artificial intelligence neural network for evaluation of the effect of Butyphthalide combined with edaravone on neurological function in patients with acute cerebral infarction","volume":"15","author":"Li","year":"2021","journal-title":"Front Neurorobot"},{"key":"10.1016\/j.pharmr.2025.100101_bib255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12868-014-0125-3","article-title":"Anti-inflammatory effects of edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia","volume":"15","author":"Yuan","year":"2014","journal-title":"BMC Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib256","article-title":"A single-center clinical study to evaluate Shenxiong glucose injection combined with edaravone in the treatment of acute large-area cerebral infarction","volume":"2021","author":"Li","year":"2021","journal-title":"Biomed Res Int"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib257","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032929","article-title":"Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: a systematic review and meta-analysis","volume":"102","author":"Li","year":"2023","journal-title":"Medicine"},{"issue":"3\u20134","key":"10.1016\/j.pharmr.2025.100101_bib258","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/21678421.2018.1425455","article-title":"Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective","volume":"19","author":"Yeo","year":"2018","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100101_bib259","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1212\/WNL.0000000000201627","article-title":"Costs and utilization of new-to-market neurologic medications","volume":"100","author":"Reynolds","year":"2023","journal-title":"Neurology"},{"issue":"9 Suppl","key":"10.1016\/j.pharmr.2025.100101_bib260","first-page":"S175","article-title":"Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion","volume":"24","author":"Brooks","year":"2018","journal-title":"Am J Manag Care"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib261","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-022-02182-3","article-title":"Patients\u2019 access to rare neuromuscular disease therapies varies across US private insurers","volume":"17","author":"Margaretos","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100101_bib262","first-page":"216","article-title":"The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: a summary from the Institute for Clinical and Economic Review\u2019s Midwest Comparative Effectiveness Public Advisory Council","volume":"29","author":"Nikitin","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100101_bib263","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.03.456","article-title":"EE157 assessing the cost-effectiveness of sodium phenylbutyrate\/taurursodiol and oral edaravone in the treatment of amyotrophic lateral sclerosis","volume":"27","author":"Suh","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100101_bib265","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s13023-024-03381-w","article-title":"Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis","volume":"19","author":"Liu","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100101_bib266","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.04.002","article-title":"Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction","volume":"22","author":"Shinohara","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.pharmr.2025.100101_bib267","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.938239","article-title":"Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: based on the TASTE study","volume":"13","author":"Shi","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100101_bib268","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/antiox9100943","article-title":"Traumatic brain injury: oxidative stress and novel anti-oxidants such as mitoquinone and edaravone","volume":"9","author":"Ismail","year":"2020","journal-title":"Antioxidants"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100101_bib269","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.2174\/0929867327666200812221022","article-title":"Drug repurposing: promises of edaravone target drug in traumatic brain injury","volume":"28","author":"Shakkour","year":"2021","journal-title":"Curr Med Chem"}],"updated-by":[{"DOI":"10.1016\/j.pharmr.2026.100114","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:54:13Z","timestamp":1773219253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725075106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":265,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0031699725075106"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100101","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Edaravone: Advances on cytoprotective effects, pharmacological properties, and mechanisms of action","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100101"}}